13F-HR filed by ANDERA PARTNERS
ANDERA PARTNERS filed this 13F-HR for the quarter ended 2026-03-31, filed 2026-05-11, with 7 holding rows worth $176,916,075.
- Accession
- 0001757283-26-000012
- Filer
- CIK 1757283
- Filed
- 2026-05-11
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2026
A holdings report, 7 entries on the cover page, a total value of $176,916,075 stated on the cover page (in dollars after the unit check, H1), rows summing to $176,916,075 with VALUE read as dollars as filed, 13F file number 028-26561. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| KESTRA MED TECHNOLOGIES LTD | G52441105 | SHS | 2,695,192 | $53,715,177 | dollars as filed | |
| EVOMMUNE INC | 30054Y107 | COMMON STOCK | 1,897,362 | $43,620,352 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 1,591,917 | $43,125,032 | dollars as filed | |
| AGOMAB THERAPEUTICS NV | 00860C102 | SPONSORED ADS | 1,538,702 | $16,140,984 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 1,818,181 | $10,090,905 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 78,125 | $8,699,219 | dollars as filed | |
| NYXOAH S A | B6S7WD106 | SHS | 522,057 | $1,524,406 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001757283-26-000012 | this filing | 2026-05-11 | acceptance time not in the bulk data set |